Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig (PM8002, BNT327) plus chemotherapy vs placebo plus chemotherapy in first-line PD-L1–negative unresectable or metastatic triple-negative breast cancer
CTR20260417Phase 3Active
- Sponsor
- BioNTech
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pumitamig in breast cancer, sponsored by BioNTech. Started Apr 2026; status: active.
02
Drugs
pumitamig
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20260417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260417.